Abstract: Methods for treatment of most bothersome symptom (MBS) associated with migraine are provided. Exemplary methods provide improvement in MBS associated with migraine within 1 month of administration og anti-CGRP antibodies of the invention. Also provided are methods for improvement of patient impression of change (PGIC) associated with migraine. Exemplary methods comprise administration of an anti-CGRP antagonistic antibody to a patient in need thereof.

Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof. This invention pertains to methods of treatment of headache disorders, such as migraine, using antibodies and fragments thereof (including Fab fragments) that specifically bind to human Calcitonin Gene Related Peptide (hereinafter “CGRP”).

Abstract: Methods for treatment of most bothersome symptom (MBS) associated with migraine are provided. Exemplary methods provide improvement in MBS associated with migraine within 1 month of administration og anti-CGRP antibodies of the invention. Also provided are methods for improvement of patient impression of change (PGIC) associated with migraine. Exemplary methods comprise administration of an anti-CGRP antagonistic antibody to a patient in need thereof.

Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Abstract: Methods for treatment or prevention of medication overuse headache are provided. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.

Abstract: A diagnostic test for a head and facial pain disorder in a human patient includes providing test strip containing one or more antibodies corresponding one or more biological markers associated with the disorder or with multiple disorders. A saliva sample is collected from the human patient and applied to the test strip. The test strip is subsequently evaluated for evidence of binding of one or more of the antibodies with any biological markers present in the saliva sample. The progression of the head and facial pain disorder in the patient may be measured by collecting and evaluating additional saliva samples over time and comparing any changes in the amount of binding activity between or among samples.

Abstract: A diagnostic test for determining the efficacy of 5HT1 agonists in a human patient exhibiting symptoms of a cranial facial pain syndrome includes the steps of collecting a sample of saliva from said human patient; and identifying whether calcitonin-gene-related peptide is present in said sample of saliva.

Abstract: A cognitive testing and assessment system includes a testing module, said testing module having an input device, a memory, and at least one cognitive test battery stored in said memory, a wireless communication module, and an assessment and response module. The wireless communication module allows the system to communicate with external devices or networks, such as the Internet, local area networks, wide area networks, satellites, or cellular networks, without a wired connection. The assessment and response center may be either integrated into the system or located in a remote centralized or regional facility that the system accesses via the wireless communication module.

Abstract: A diagnostic test for head and facial pain includes providing a series of antibodies to several biological markers on a test strip, collecting a sample of saliva, and applying the saliva sample to the series of antibodies. If one or more of the anticipated biological markers are present in the sample of saliva, those markers bind to their correlating antibodies thereby providing an indicator of the presence and amount of a particular biological marker in the patient's saliva upon evaluation of the test strip. When applied to a suitable biosensor, the described method can generate an electrical signal that can subsequently be transmitted to other devices. The biosensor includes a substrate that is coated with D-poly lysine on which the various antibodies are randomly arranged. The interaction of biological marker and antibody alters the electrical impedance of the substrate.

Abstract: A biometric testing and monitoring device includes a biosensor with a substrate having an electrical impedance and a coating, at least a first antibody corresponding to at least a first biological marker on said coating, the antibody being operative for binding with the biological marker present in a sample of saliva from a human patient; and a microprocessor in communication with the biosensor and a network. In an alternate embodiment, the device also includes a cognitive testing module in communication with the microprocessor.

Abstract: A method of preventing the headache phase of migraine in a human comprises administration of a 5HT1 receptor agonist or administration of an over-the-counter or nonprescription drug to said human exhibiting prodrome symptoms of migraine. Suitably, the method comprises administration of a migraine headache phase-preventing effective amount of the 5HT1 agonist or over-the-counter or nonprescription drug. There is disclosed a preemptive prophylaxis migraine method using the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; Mathematical Processing Task; and interpreting the results as a percent of baseline indicator of need for prophylaxis.

Abstract: A method for measuring cognitive efficiency uses the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; and Mathematical Processing Task. A device for measuring cognitive efficiency includes a microprocessor having a memory; the aforementioned cognitive tests loaded into the memory; a baseline stored in the memory, means for computing the score on a run of these tests and for storing the score in the memory; the means for computing being operative for comparing the score to the stored baseline; and means for indicating a cognitive change from the baseline. Changes in cognitive efficiency may be measured by comparing the results of the cognitive tests to a baseline.

Abstract: A preemptive prophylaxis migraine method uses the following cognitive tests: Simple Reaction Time; Running Memory Continuous Performance Task; Matching to Sample; Mathematical Processing Task; and interprets the results as a percent of baseline indicator of need for prophylaxis. A preemptive prophylaxis migraine device includes a microprocessor having a memory; the aforementioned cognitive tests loaded into the memory; means for computing the score on a trial of these tests to establish a baseline, for storing the baseline in the memory, for computing the score of a subsequent trial of the tests, and for comparing the same to the stored baseline; and means for indicating a cognitive change.

Abstract: A method for enhancing serum dehydroepiandrosterone (DHEA) levels in human beings resulting in improved host response to infection and resistance to pathogenic and opportunistic infectious organisms. The serum concentration of DHEA is elevated through the use of topically applied preparations containing the steroid, progesterone, through two different types of electronic stimulators applied to specific acupuncture points on an individual's body, or by combination of the two methods. One or more of the methods may be applicable to the whole.

Abstract: A light emitting relaxation device and method for placing a subject in a relaxed state. The relaxation device includes a portable mask that has a flashing light source. When the mask is positioned on the subject's head a flashing light, have a preselected color, is emitted into the subject's eyes. The color is selected to increase beta endorphins in the bloodstream of the subject. The mask, preferably, is totally self-contained having built-in controls to set the speed, intensity and duration of the flashing light.